Roche's third-quarter earnings show that sales in its International region, which includes China, grew 20% in the period, boosted by an expansion in coverage for its anticancer drugs.
The stellar performance was “mainly driven by significantly increased numbers of patients benefiting from Roche cancer drugs in China with...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

